Literature DB >> 11706969

Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: no requirement for proapoptotic interleukin-1beta in neurodegeneration.

M D Nguyen1, J P Julien, S Rivest.   

Abstract

Recent studies have demonstrated the activation of caspase-1 and caspase-3 in mice expressing mutant superoxide dismutase 1 (SOD1), models of amyotrophic lateral sclerosis. Caspase-1 converts the prointerleukin-1beta into a potent proinflammatory molecule involved in the innate immune response and in neurodegenerative diseases. We report on the chronic expression of interleukin-1beta mRNA in the spinal cord of SOD1G37R mice, together with robust mRNA expression for the nuclear factor-kappaB (NF-kappaB) inhibitor IkappaBalpha, for other proinflammatory cytokines and chemokines (interleukin-6, tumor necrosis factor-alpha, monocyte chemoattractant protein-1) and for the toll-like receptor TLR2 involved in innate immunity. To further assess the interleukin-1beta contribution to neurodegeneration, we generated mice expressing SOD1G37R in a context of interleukin-1beta gene knockout. Surprisingly, the absence of interleukin-1beta had no effect on the life span of SOD1G37R mice, nor on the extent of motor axon degeneration at age 7 and 10 months. Whereas neither compensatory induction of the interleukin-1alpha mRNA nor increases in mRNA levels for IkappaBalpha, tumor necrosis factor-alpha and macrophage chemoattractant protein-1 occurred as a result of interleukin-1beta gene disruption, enhanced levels of TLR2 mRNA were detected in SOD1G37R mice lacking interleukin-1beta. We conclude that interleukin-1beta does not directly contribute to motor neuron degeneration in SOD1G37R mice, but it may act as a modulator of the innate immune response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11706969     DOI: 10.1002/ana.1256

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  26 in total

Review 1.  Programmed cell death in amyotrophic lateral sclerosis.

Authors:  Christelle Guégan; Serge Przedborski
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 2.  The immunology of neurodegeneration.

Authors:  Eva Czirr; Tony Wyss-Coray
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 3.  Motor neuron trophic factors: therapeutic use in ALS?

Authors:  Thomas W Gould; Ronald W Oppenheim
Journal:  Brain Res Rev       Date:  2010-10-21

Review 4.  Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis.

Authors:  Jason R Thonhoff; Luis Ojeda; Ping Wu
Journal:  Curr Stem Cell Res Ther       Date:  2009-09       Impact factor: 3.828

Review 5.  Redox modifier genes and pathways in amyotrophic lateral sclerosis.

Authors:  Barrie J Carter; Pervin Anklesaria; Stephanie Choi; John F Engelhardt
Journal:  Antioxid Redox Signal       Date:  2009-07       Impact factor: 8.401

Review 6.  Glial cells in amyotrophic lateral sclerosis.

Authors:  T Philips; J D Rothstein
Journal:  Exp Neurol       Date:  2014-05-22       Impact factor: 5.330

Review 7.  T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?

Authors:  Stanley H Appel; David R Beers; Jenny S Henkel
Journal:  Trends Immunol       Date:  2009-10-31       Impact factor: 16.687

Review 8.  Inflammation in the early stages of neurodegenerative pathology.

Authors:  Preeti J Khandelwal; Alexander M Herman; Charbel E-H Moussa
Journal:  J Neuroimmunol       Date:  2011-08-05       Impact factor: 3.478

Review 9.  Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis.

Authors:  Kristopher G Hooten; David R Beers; Weihua Zhao; Stanley H Appel
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

10.  Does neuroinflammation fan the flame in neurodegenerative diseases?

Authors:  Tamy C Frank-Cannon; Laura T Alto; Fiona E McAlpine; Malú G Tansey
Journal:  Mol Neurodegener       Date:  2009-11-16       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.